Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI-88 plus Dacarbazine in Metastatic Melanoma
NCT00130442Phase 2Completed
- Sponsor
- Cellxpert Biotechnology Corp.
- Start
- Jun 2005
- Primary completion
- Oct 2010
- Modality
- Bivalent/Multivalent Binders
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of Muparfostat in melanoma (2 arms), sponsored by Cellxpert Biotechnology Corp. Primary endpoint: Non-progression Rate After Six Cycles at 5 months. Started Jun 2005; status: completed.
02
Drugs
Muparfostat
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00130442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130442.